Key result
Reboxetine significantly lowered the dose of phenylephrine (0.25 vs 0.64 µg/kg/min) and nitroprusside (0.40 vs 1.10 µg/kg/min) required to reach BP changes of 12.5 mm Hg compared to placebo (P<0.01).
Why the study?
Does reboxetine alter baroreflex control of heart rate and sympathetic traffic in healthy subjects?
Population
Healthy subjects
Comparison
Reboxetine 8 mg ingested 12 hours and 1 hour… vs Placebo
Design
RCT, randomized, crossover, double-blind
Authors
Loading...
NET inhibition resets baroreflex to higher BP and attenuates sympathetic vasoconstriction; extends mechanistic insight into vasomotor regulation in humans.
RCT
Double-blind
crossover
Does reboxetine alter baroreflex control of heart rate and sympathetic traffic in healthy subjects?
Absolute Event Rate: 0.25% vs 0.64%
p-value: p=<0.01
Norepinephrine transporter inhibition with reboxetine profoundly reduces baroreflex control of sympathetic vasomotor tone, providing a novel mechanism for increased sensitivity to vasoactive medications.
Tank et al. (2003) conducted an RCT in Healthy subjects. Reboxetine vs. Placebo was evaluated on Dose of phenylephrine to reach BP changes of 12.5 mm Hg (microg/kg/min) (p=<0.01). Reboxetine significantly lowered the dose of phenylephrine (0.25 vs 0.64 µg/kg/min) and nitroprusside (0.40 vs 1.10 µg/kg/min) required to reach BP changes of 12.5 mm Hg compared to placebo (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: